Atavistik Bio

About Atavistik Bio

Atavistik Bio uses its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform to discover and develop precision allosteric small‑molecule therapeutics by identifying cryptic allosteric pockets with metabolite‑guided and AI‑enabled methods. The integrated computational‑experimental workflow accelerates hit identification and lead optimization for high‑unmet‑need targets in oncology and rare diseases, enabling partners to drug previously intractable proteins with improved selectivity and tolerability.

<problem>Traditional small‑molecule drug discovery often targets the active site of proteins, leaving roughly 90% of disease‑relevant proteins undruggable because suitable binding pockets are not apparent. Identifying functional allosteric sites that can be modulated by small molecules is a major bottleneck, limiting the development of selective and potent therapies for high‑unmet‑need diseases such as rare genetic disorders and certain cancers.</problem> <solution>Atavistik Bio addresses this gap with its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform, which uses metabolites as molecular baits to reveal cryptic allosteric pockets across diverse protein classes. The platform combines computational modeling, AI‑enabled structure‑based design, and experimental validation to rapidly translate identified pockets into precision allosteric small‑molecule candidates. By focusing on natural protein regulators, the approach accelerates discovery of highly selective modulators that can differentiate mutant from wild‑type proteins, improving efficacy and tolerability. The integrated workflow enables fast iteration from pocket identification to lead optimization, supporting internal programs in oncology and rare diseases and providing a foundation for partnership‑driven expansion into additional therapeutic areas.</solution> <features> - Metabolite‑guided screening that pinpoints functional allosteric sites not detectable by conventional methods - AI‑powered structure‑based drug design engine for rapid generation of selective small‑molecule modulators - Integrated computational‑experimental pipeline that streamlines pocket validation, hit identification, and lead optimization - Capability to develop mutant‑selective inhibitors (e.g., JAK2 V617F, AKT1 E17K) that spare wild‑type activity - Versatile platform applicable to a broad range of protein targets, enabling expansion beyond oncology and rare diseases </features> <target_audience>Primary customers are pharmaceutical and biotech companies seeking to drug previously intractable targets, particularly in precision oncology and rare disease programs, as well as research partners interested in leveraging allosteric discovery technology.</target_audience>

What does Atavistik Bio do?

Atavistik Bio uses its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform to discover and develop precision allosteric small‑molecule therapeutics by identifying cryptic allosteric pockets with metabolite‑guided and AI‑enabled methods. The integrated computational‑experimental workflow accelerates hit identification and lead optimization for high‑unmet‑need targets in oncology and rare diseases, enabling partners to drug previously intractable proteins with improved selectivity and tolerability.

Where is Atavistik Bio located?

Atavistik Bio is based in Cambridge, United States.

When was Atavistik Bio founded?

Atavistik Bio was founded in 2021.

How much funding has Atavistik Bio raised?

Atavistik Bio has raised $40.0M.

Location
Cambridge, United States
Founded
2021
Funding
$40.0M
Employees
39 employees
Investors
Nextech Invest
AB

Atavistik Bio

Atavistik Bio uses its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform to discover and develop precision allosteric small‑molecule therapeutics by identifying cryptic allosteric pockets with metabolite‑guided and AI‑enabled methods. The integrated computational‑experimental workflow accelerates hit identification and lead optimization for high‑unmet‑need targets in oncology and rare diseases, enabling partners to drug previously intractable proteins with improved selectivity and tolerability.

Cambridge, United StatesFounded 2021393K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 1 month ago

Funding

$40.0M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Traditional small‑molecule drug discovery often targets the active site of proteins, leaving roughly 90% of disease‑relevant proteins undruggable because suitable binding pockets are not apparent. Identifying functional allosteric sites that can be modulated by small molecules is a major bottleneck, limiting the development of selective and potent therapies for high‑unmet‑need diseases such as rare genetic disorders and certain cancers.

Solution

Atavistik Bio addresses this gap with its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform, which uses metabolites as molecular baits to reveal cryptic allosteric pockets across diverse protein classes. The platform combines computational modeling, AI‑enabled structure‑based design, and experimental validation to rapidly translate identified pockets into precision allosteric small‑molecule candidates. By focusing on natural protein regulators, the approach accelerates discovery of highly selective modulators that can differentiate mutant from wild‑type proteins, improving efficacy and tolerability. The integrated workflow enables fast iteration from pocket identification to lead optimization, supporting internal programs in oncology and rare diseases and providing a foundation for partnership‑driven expansion into additional therapeutic areas.

Target Audience

Primary customers are pharmaceutical and biotech companies seeking to drug previously intractable targets, particularly in precision oncology and rare disease programs, as well as research partners interested in leveraging allosteric discovery technology.

Features

  • Metabolite‑guided screening that pinpoints functional allosteric sites not detectable by conventional methods
  • AI‑powered structure‑based drug design engine for rapid generation of selective small‑molecule modulators
  • Integrated computational‑experimental pipeline that streamlines pocket validation, hit identification, and lead optimization
  • Capability to develop mutant‑selective inhibitors (e.g., JAK2 V617F, AKT1 E17K) that spare wild‑type activity
  • Versatile platform applicable to a broad range of protein targets, enabling expansion beyond oncology and rare diseases
1
This profile is AI-generated and may contain inaccuracies.